Get started

Financials · AXSM

Axsome Therapeutics Inc. (AXSM) financials

For the twelve months ended Sep 30, 2026, Axsome Therapeutics Inc. reported $865.27M of revenue and -$157.29M of net income.

Revenue, TTM
$865.27M
Revenue growth, YoY
+54.2%
Net income, TTM
-$157.29M
Net margin
-18.2%
Free cash flow, TTM
-$82.61M
EPS, diluted, TTM
-$3.05
Cash
$313.86M
Total debt
$188.07M
P/S
8.14
Market cap
$7.05B
Annual revenue$638.50M
FY2022FY2025
Annual net income-$183.17M
FY2016FY2025
Annual free cash flow-$93.89M
FY2016FY2025

AXSM revenue and earnings growth

AXSM revenueQ3 2026$259.69M

Quarter YoY
+51.9%
QoQ
+18.9%
FY YoY
+65.5%

AXSM revenue was $259.69M in fiscal Q3 2026 (ended Sep 30, 2026), up 51.9% from a year earlier and up 18.9% from the prior quarter. For the full fiscal 2025 it was $638.50M, up 65.5% from fiscal 2024. It rose in each of the last 3 fiscal years.

AXSM net incomeQ3 2026-$12.88M

AXSM net income was -$12.88M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$47.23M a year earlier. For the full fiscal 2025 it was -$183.17M, compared with -$287.22M in fiscal 2024.

AXSM EPSQ3 2026-$0.25

AXSM diluted EPS was -$0.25 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.94 a year earlier. For the full fiscal 2025 it was -$3.68, compared with -$5.99 in fiscal 2024.

AXSM free cash flowQ3 2026-$9.67M

AXSM free cash flow was -$9.67M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $988.0K a year earlier. For the full fiscal 2025 it was -$93.89M, compared with -$128.68M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$638.50M$385.69M$270.60M$50.04M------
Cost of revenue---$5.20M------
Gross profit---$44.84M------
Research and development$183.28M$187.08M$97.94M$57.95M$58.06M$70.24M$53.65M$23.50M$19.96M$21.20M
Selling, general and admin$570.60M$411.36M$323.12M$159.25M$66.65M$28.90M$13.60M$9.35M$7.21M$6.34M
Operating income-$166.76M-$280.56M-$231.82M-$179.80M-$124.71M-$99.14M-$67.25M-$32.85M-$27.16M-$27.54M
Interest expense-$15.93M-$21.58M-$20.03M-$9.66M------
Pre-tax income-$183.70M-$287.13M-$238.28M-$187.13M-$130.40M-----
Income tax-$530.0K$85.0K$960.0K$0$0$0$0$0$0$0
Net income-$183.17M-$287.22M-$239.24M-$187.13M-$130.40M-$102.90M-$68.35M-$30.97M-$28.94M-$27.20M
EPS, basic-$3.68-$5.99-$5.27-$4.60-$3.47-$2.77-$2.01-$1.15-$1.27-$1.42
EPS, diluted-$3.68-$5.99-$5.27-$4.60-$3.47-$2.77-$2.01-$1.15-$1.27-$1.42
Diluted shares49.7M47.9M45.4M40.7M37.6M37.2M34.0M26.9M22.8M19.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$322.93M$315.35M$386.19M$200.84M$86.47M$183.88M$219.97M$13.97M$34.02M$36.62M
Receivables$224.46M$142.00M$94.82M$37.70M------
Inventory$27.94M$15.73M$15.13M$4.32M------
Current assets$588.99M$485.06M$504.26M$245.64M$86.52M$184.02M$220.38M$15.22M$35.30M$38.00M
Goodwill$12.04M$12.04M$12.04M$10.31M------
Total assets$689.80M$568.50M$588.24M$331.48M$87.79M$186.13M$220.55M$15.38M$35.56M$38.21M
Current liabilities$378.84M$230.10M$138.85M$96.56M$23.07M$23.44M$24.49M$10.82M$12.18M$7.17M
Short-term debt$70.00M$0----$2.60M$3.29M$3.27M$269.2K
Long-term debt$117.75M$180.71M$178.07M$94.26M$49.09M$48.32M$17.33M$3.62M$6.66M$9.47M
Total debt$187.75M$180.71M$178.07M$94.26M$49.09M$48.32M$19.93M$6.91M$9.93M$9.74M
Total liabilities$601.51M$511.48M$397.26M$221.92M$72.15M$72.34M$41.83M$14.44M$18.84M$16.64M
Shareholders' equity$88.30M$57.02M$190.98M$109.56M$15.63M$113.79M$178.72M$937.9K$16.72M$21.57M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$93.41M-$128.41M-$145.08M-$116.51M-$108.23M-$78.46M-$46.38M-$30.05M-$26.47M-$21.28M
Capital expenditures$480.0K$270.0K$582.0K$702.0K$308.0K$45.9K$16.1K$32.7K$9.9K$104.6K
Free cash flow-$93.89M-$128.68M-$145.66M-$117.21M-$108.53M-$78.50M-$46.39M-$30.09M-$26.48M-$21.39M
Investing cash flow-$480.0K-$270.0K-$582.0K-$53.70M-$308.0K-$45.9K-$16.1K-$32.7K-$9.9K-$104.6K
Financing cash flow$101.47M$57.84M$331.01M$284.58M$11.13M$42.41M$252.39M$10.03M$23.88M$9.97M
Stock-based compensation$93.75M$85.22M$62.62M$37.73M$20.80M$14.76M$6.12M$1.75M$2.07M$2.03M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY65.5%42.5%440.8%-------
Gross margin---89.6%------
Operating margin-26.1%-72.7%-85.7%-359.3%------
Net margin-28.7%-74.5%-88.4%-374.0%------
Free cash flow margin-14.7%-33.4%-53.8%-234.3%------
Return on equity-207.5%-503.8%-125.3%-170.8%-834.3%-90.4%-38.2%-3301.5%-173.1%-126.1%
Return on assets-26.6%-50.5%-40.7%-56.5%-148.5%-55.3%-31.0%-201.3%-81.4%-71.2%
Current ratio1.552.113.632.543.757.859.001.412.905.30
Debt to equity2.133.170.930.863.140.420.117.370.590.45

Source: XBRL data Axsome Therapeutics Inc. files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

AXSM peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
AXSM$865.27M+54.2%-$157.29M-18.2%$7.05B
ALKS$1.75B+15.3%-$351.0K-0.0%$7.76B
SUPN$1.37B+16.3%$450.00M32.8%$3.26B
HRMY$989.36M+19.8%$178.60M18.1%$1.98B
VNDA$229.28M+8.1%-$274.83M-119.9%$247.3M
NBIX$3.70B+38.0%$702.50M19.0%$17.09B
ACAD$1.20B+14.8%$362.23M30.1%$2.85B

AXSM FAQ

8 questions
  • What is AXSM revenue?
    Axsome Therapeutics Inc. (AXSM) reported $865.27M of revenue for the twelve months ended Sep 30, 2026. That is up 54.2% from the year before. Revenue for fiscal 2025 was $638.50M.
  • Is AXSM profitable?
    No. Axsome Therapeutics Inc. reported a net loss of $157.29M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does AXSM have?
    Axsome Therapeutics Inc. reported $313.86M in cash and cash equivalents and $188.07M of debt on its most recent balance sheet in SEC filings.
  • How fast is AXSM revenue growing?
    Axsome Therapeutics Inc.'s revenue changed +65.5% in fiscal 2025, to $638.50M.
  • What is AXSM free cash flow?
    Axsome Therapeutics Inc. generated -$82.61M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$81.77M less capital expenditures.
  • What is AXSM earnings per share?
    Diluted earnings per share were -$3.05 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did AXSM last report financial results?
    The latest statements here come from Axsome Therapeutics Inc.'s 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this AXSM financial data come from?
    Quantisnow builds these statements from the structured XBRL data Axsome Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.